Alliance Pharma (AIM:APH) – interesting acquisition of MacuVision
The AIM quoted speciality pharmaceutical company has announced the acquisition of MacuVision Europe Limited which sells an eye care treatment designed to be taken by sufferers of dry age-related macular degeneration and other eye conditions. It looks an interesting little acquisition.
The initial consideration is £5.5m plus the net asset value of MacuVision at completion (estimated at £nil) and deferred contingent consideration of up to £6.0 million. MacuShield is an eye care treatment designed to be taken by sufferers of dry age-related macular degeneration and other eye conditions.
In the twelve months to 31 December 2014, MacuShield sales were £3.4m
MacuShield is a once-a-day capsule that…
Previous article Next article
